Vascular and myocardial inflammation are significantly increased in Acute Coronary Syndrome
(ACS) patients, are closely correlated to LDL-C levels, and are associated with these adverse
consequences in the post-ACS patient population. Serum proprotein convertase subtilisin/kerin
type 9 (PCSK9) levels are also increased in ACS, may raise LDL-C, and the investigators'
pre-clinical studies indicate that PCSK9 is also a potent inducer of vascular inflammation.
The addition of the PCSK9 antibody evolocumab, currently approved to lower LDL-C in certain
patient populations, to current medical therapies would appear to be of particular benefit in
an important subset of ACS patients, those with non-ST elevation myocardial infarction
(NSTEMI) by markedly reducing LDL-C, stabilizing vulnerable plaque, and limiting
inflammation-associated myocardial cell loss and resultant dysfunction.